Repare Therapeutics
RPTX
RPTX was delisted on the 27th of January, 2026.
0 hedge funds and large institutions have $0 invested in Repare Therapeutics in 2026 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 45 closing their positions.
58.37% less ownership
Funds ownership: 58.37% → 0% (-58%)
100% less funds holding
Funds holding: 46 → 0 (-46)
100% less funds holding in top 10
Funds holding in top 10: 4 → 0 (-4)
100% less capital inflows, than outflows
Capital inflows: $0 | Capital outflows: $65.1M
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 45
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BVF Inc
San Francisco,
California
|
-$26.9M |
| 2 |
Blue Owl Capital Holdings
New York
|
-$8.95M |
| 3 |
OrbiMed
New York
|
-$8.64M |
| 4 |
Redmile Group
San Francisco,
California
|
-$4.12M |
| 5 |
Rangeley Capital
New Canaan,
Connecticut
|
-$3.35M |
RPTX Hedge Fund Activity: Q1 2026 in Review
0 of the 8,220 institutional investors tracked by Wall St. Rank reported a position in Repare Therapeutics (RPTX) for Q1 2026, worth a combined $0 — down 100% from $65.4M a quarter earlier.
Sellers outnumbered buyers: 45 funds closed out of RPTX and 0 opened new positions — a net loss of 45 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was BVF Inc, exiting entirely with an estimated $26.9M sold.
- 0 institutional investors held Repare Therapeutics (RPTX) as of Q1 2026, down from 46 in Q4 2025.
- Funds reported $0 of Repare Therapeutics stock for Q1 2026, down 100% quarter-over-quarter.
- 0 funds opened new Repare Therapeutics positions in Q1 2026 and 45 closed out, a net change of -45 holders.
- The largest Repare Therapeutics seller in Q1 2026 was BVF Inc, an estimated $26.9M sold.
Based on aggregated 13F filings for Q1 2026.